TERN — Terns Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $305.68m
- -$52.49m
- 35
- 35
- 23
- 21
Annual income statement for Terns Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 37 | 50.9 | 62 | 103 | 102 |
| Operating Profit | -37 | -49.9 | -62 | -103 | -102 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -39.8 | -49.6 | -60 | -90 | -88.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -40.6 | -50.2 | -60.3 | -90.2 | -88.9 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -40.1 | -50.2 | -60.3 | -90.2 | -88.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -29.4 | -50.2 | -60.3 | -90.2 | -88.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.29 | -2.21 | -1.67 | -1.27 | -1.12 |